Skip to main content

Justin Balko Archives

Cancer Center investigators awarded Komen grants

Oct. 11, 2018—Four Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.

Read more


Study seeks to boost breast tumor immune response

Feb. 8, 2018—Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.

Read more


Breast cancer program lands new research grants

Mar. 23, 2017—Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.

Read more


V Foundation grants bolster cancer initiatives

Nov. 17, 2016—Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.

Read more


Study details rare heart risk of certain cancer therapies

Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...

Read more


Precision medicine already changing cancer treatment strategies

May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

Read more


Study explores how some breast cancers resist treatment

Apr. 21, 2016—A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

Read more


Melanoma response to immune therapy

Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

Read more


VICC’s Balko named a Susan G. Komen ‘Pink Tie Guy’

Dec. 10, 2015—Justin Balko, Pharm.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been named a member of the 2016 class of Pink Tie Guys by the Greater Nashville Affiliate of Susan G. Komen, a nonprofit organization dedicated to breast cancer research and patient support.

Read more


Gene mutation linked to breast cancer therapy resistance

Nov. 20, 2014—A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.

Read more


VICC investigators earn breast cancer grants

Oct. 23, 2014—The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies.

Read more


VICC investigators land Komen breast cancer research grants

Jul. 31, 2014—Two Vanderbilt-Ingram Cancer Center investigators have received multi-year breast cancer research grants from the Susan G. Komen for the Cure Breast Cancer Foundation.

Read more


Page 1 of 212

Recent Stories from VUMC News and Communications Publications

Our amazing skin

Vanderbilt Medicine

Our amazing skin

Biology and the beat

Vanderbilt Medicine

Biology and the beat

Community care

Vanderbilt Nurse

Community care

Survive and thrive

Hope

Survive and thrive

more